FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Fulgent Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$20.10+0.29 (+1.46%)
Close on Oct 19, 2026
- Market cap
- $562.90M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
40.6%−38.1 pts over 5 years
Operating margin
-28.2%−97.0 pts over 5 years
Net margin
-18.8%−69.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.8% | -19.5% | -5.2% | +42.2% | |
| Gross profit | +22.1% | -29.1% | -17.0% | +40.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -17.9% | 65.7% | -5.4% | |
| Return on assets | -16.7% | 54.3% | -5.0% | |
| Current ratio | 7.88 | 4.02 | 6.48 | |
| Debt to equity | – | – | 0.00 | |
| Net debt to EBITDA | – | – | 0.72× | |
| Interest coverage | – | 14507.9× | -1214.6× | |
| Capex to revenue | 20.7% | 8.3% | 7.0% | |
| Diluted shares | 14M | 24M | 31M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Fulgent Genetics generated $941.80M from operations and spent $238.19M on capital expenditure, dividends and share buybacks. 54% of that went back into the business.
Generated
$941.80M
Used
$238.19M
Capital expenditure$127.68M54%Dividends$00%Share buybacks$110.51M46%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-18.8%
×Asset turnover0.27×
×Equity multiplier1.08×
=Return on equity, FY2025-5.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -18.8% | 0.27× | 1.08× | -5.4% |
| FY2024 | -15.1% | 0.23× | 1.08× | -3.8% |
| FY2023 | -58.0% | 0.22× | 1.09× | -14.0% |
| FY2022 | 23.2% | 0.46× | 1.10× | 11.8% |
| FY2021 | 51.1% | 1.00× | 1.15× | 58.7% |
| FY2020 | 50.8% | 1.07× | 1.21× | 65.7% |
| FY2019 | -1.3% | 0.46× | 1.07× | -0.6% |
| FY2018 | -26.3% | 0.38× | 1.05× | -10.6% |
| FY2017 | -13.4% | 0.33× | 1.06× | -4.6% |
| FY2016 | -29.3% | 0.57× | 1.07× | -17.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$60.51M
- Cash generatingOperating cash flow above zero-$101.64M
- Return on assets improvedROA up on the prior year-3.5% → -5.0%
- Earnings backed by cashOperating cash flow above net income-$101.64M vs -$60.51M
- Less leverageLong-term debt to assets fell0.2% → 0.2%
- Better liquidityCurrent ratio rose4.85 → 6.48
- No dilutionShare count did not rise30M → 31M
- Gross margin improvedGross margin up on the prior year37.82% → 40.56%
- More efficientAsset turnover rose0.23 → 0.26